Description

Inflectra (infliximab-dyyb) is a medication given as an intravenous (IV) infusion to treat the following conditions:

• Crohn’s disease
• Pediatric Crohn’s disease
• Ulcerative colitis
• Pediatric ulcerative colitis
• Rheumatoid arthritis
• Ankylosing spondylitis
• Psoriatic arthritis
• Plaque psoriasis

Directions

Your doctor will determine an appropriate treatment regimen for you, including Inflectra dosing. Inflectra will be administered via an IV infusion by a healthcare professional. Inform your doctor of any questions or concerns you may have about the medication.

Ingredients

The active ingredient in Inflectra is infliximab-dyyb.

Inactive ingredients include dibasic sodium phosphate dihydrate, monobasic sodium phosphate monohydrate, polysorbate 80, and sucrose.

Contraindications

Patients with moderate or severe heart failure should not receive Inflectra doses that exceed 5 mg per kg.

Additionally, patients who are allergic to infliximab or any of the other ingredients in Inflectra should not receive the medication.

Cautions

• Inflectra contains the following FDA Boxed Warning:
• The risk for serious infections that can result in hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens, is increased.
• Inflectra should be stopped if a patient develops a serious infection.
• Patients should receive a test for latent TB. If the test is positive, TB treatment should be initiated before starting Inflectra. All patients should be monitored for active TB during treatment, even if the latent TB test is negative.
• Children and adolescent patients treated with tumor necrosis factor (TNF) blockers such as infliximab have developed lymphoma and other malignancies; some have been fatal.
• Some patients treated with TNF blockers such as infliximab developed fatal hepatosplenic T-cell lymphoma (HSTCL). Almost all had received azathioprine or 6-mercaptopurine with a TNF blocker at or before diagnosis. Most of the cases were reported in patients with Crohn’s disease or ulcerative colitis, the majority of whom were adolescent or young adult males.
• Before you begin treatment with Inflectra, inform your doctor of:
• All the prescription and over-the-counter medications you take
• Your allergies
• Your current health problems and past medical history
• Your pregnancy or breastfeeding status
• Inflectra is associated with the following warnings and precautions:
• Serious infections, including invasive fungal infections
• Cancers
• Reactivation of hepatitis B virus
• Liver problems
• Heart failure
• Abnormal blood cell counts
• Hypersensitivity reactions, including anaphylaxis or serum sickness-like reactions
• Cardiovascular and cerebrovascular reactions, including heart attacks and arrhythmias
• Demyelinating disease
• Lupus-like syndrome
• Live vaccinations should not be administered to patients who are being treated with Inflectra.

Side Effects

Infections, infusion-related reactions, headache, and abdominal pain are common Inflectra side effects; however, other side effects may also occur. Immediately inform your doctor of any side effects that bother you or won’t go away.

Ask your doctor about Inflectra.

Reference:

Inflectra. New York, NY: Pfizer Labs; 2023.

About Dr. Savannah Muncy (Page Author)

Dr. Muncy (PharmD) studied science and education as an undergraduate before attending the Appalachian College of Pharmacy where she completed her PharmD in three years. She is currently using her pharmacy and healthcare expertise to write medical content for clients all around the world. She is focused on delivering the most current, accurate, and engaging information to healthcare professionals and patients. Read More....

Product Code : 14558